ReviewCancer metastasis reviews2010
Perspectives on the mesenchymal origin of metastatic cancer.
Review in Cancer metastasis reviews, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 54 citations in OpenAlex.
- The Warburg hypothesis and the emergence of the mitochondrial metabolic theory of cancer.Journal of bioenergetics and biomembranes · 2025Review
- Metabolic factors associated with the prognosis of oligometastatic patients treated with stereotactic body radiotherapy.Cancer metastasis reviews · 2023Review
- Article
- Can the Mitochondrial Metabolic Theory Explain Better the Origin and Management of Cancer than Can the Somatic Mutation Theory?Metabolites · 2021Article
- Cancer and stem cells.Experimental biology and medicine (Maywood, N.J.) · 2021Review
- The stressful tumour environment drives plasticity of cell migration programmes, contributing to metastasis.The Journal of pathology · 2020Review
- Consideration of Ketogenic Metabolic Therapy as a Complementary or Alternative Approach for Managing Breast Cancer.Frontiers in nutrition · 2020Review
- Significant Neutrophilic Emperipolesis in Squamous Cell Carcinoma.Case reports in oncological medicine · 2018Article
- Press-pulse: a novel therapeutic strategy for the metabolic management of cancer.Nutrition & metabolism · 2017Article
- The Dark Side of Cell Fusion.International journal of molecular sciences · 2016Review
- Article
- Cancer as a mitochondrial metabolic disease.Frontiers in cell and developmental biology · 2015Article
- Hafnium oxide nanoparticles: toward an in vitro predictive biological effect?Radiation oncology (London, England) · 2014Article
- Cancer as a metabolic disease: implications for novel therapeutics.Carcinogenesis · 2014Review
- Should EMT of Cancer Cells Be Understood as Epithelial-Myeloid Transition?Journal of Cancer · 2014Review
- Gene expression profiles in canine mammary carcinomas of various grades of malignancy.BMC veterinary research · 2013Article
- On the origin of cancer metastasis.Critical reviews in oncogenesis · 2013Review
- Janus-faced microglia: beneficial and detrimental consequences of microglial phagocytosis.Frontiers in cellular neuroscience · 2013Article
- Establishment of animal model for the analysis of cancer cell metastasis during radiotherapy.Radiation oncology (London, England) · 2012Article
- Modeling sarcomagenesis using multipotent mesenchymal stem cells.Cell research · 2012Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
Emerging evidence suggests that many metastatic cancers arise from cells of the myeloid/macrophage lineage regardless of the primary tissue of origin. A myeloid origin of metastatic cancer stands apart from origins involving clonal evolution or epithelial-mesenchymal transitions. Evidence is reviewed demonstrating that numerous human cancers express multiple properties of macrophages including phagocytosis, fusogenicity, and gene/protein expression. It is unlikely that the macrophage properties expressed in metastatic cancers arise from sporadic random mutations in epithelial cells, but rather from damage to an already existing mesenchymal cell, e.g., a myeloid/macrophage-type cell. Such cells would naturally embody the capacity to express the multiple behaviors of metastatic cells. The view of metastasis as a myeloid/macrophage disease will impact future cancer research and anti-metastatic therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.